MCUJF Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 19:27):

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States...

Stats
Šios dienos apimtis	2 800.00
Vidutinė apimtis	1 274.00
Rinkos kapitalizacija	7.72M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $0 ) 2024-05-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.57
ATR14	$0 (0.00%)

Medicure Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Medicure Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$21.69M
Bruto pelnas:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2023
Pajamos:	$21.69M
Bruto pelnas:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2022
Pajamos:	$23.07M
Bruto pelnas:	$16.08M (69.69 %)
EPS:	$0.130

FY	2021
Pajamos:	$21.74M
Bruto pelnas:	$12.71M (58.46 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

Medicure Inc.

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.